Literature DB >> 3546580

Unspecific binding of group B streptococcal cocytolysin (CAMP factor) to immunoglobulins and its possible role in pathogenicity.

D Jürgens, B Sterzik, F J Fehrenbach.   

Abstract

The protein B of group B streptococci can bind in a nonimmune reaction to Ig of the IgG and IgM classes of various mammalian species (i.e., human, mouse, rabbit, and bovine). Protein B binding involves the Fc parts of both IgG and IgM molecules. Monoclonal or polyclonal IgG or IgM and the IgM-FC5 mu fragment of human myeloma protein combined with the protein B thereby inhibiting protein B-induced hemolysis in the CAMP reaction. The protein B/Ig complex can be dissociated with 1% Triton or guanidine-HCl (6 M). Mice infected intraperitoneally with sublethal doses of group B streptococci (GBS) and that received seven repeated intravenous injections of highly purified protein B during the first 9 h of infection developed fatal septicemia within 24 h with colony counts of up to 10(8) CFU/ml in the blood. Animals treated in the same way with either PBS or trypsinized protein B recovered. The protein B itself was not pathogenic when injected into healthy mice. Tissue sections of liver or spleen from mice infected with a lethal dose of GBS revealed the presence of protein B together with large numbers of cocci when stained by the peroxidase method using specific antibodies raised against purified protein B in the rabbit.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3546580      PMCID: PMC2188285          DOI: 10.1084/jem.165.3.720

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

Review 1.  Group B streptococcal infection in humans.

Authors:  H W Wilkinson
Journal:  Annu Rev Microbiol       Date:  1978       Impact factor: 15.500

2.  Group B streptococcal neonatal and infant infections.

Authors:  R A Franciosi; J D Knostman; R A Zimmerman
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

3.  Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants.

Authors:  C J Baker; F F Barrett; R C Gordon; M D Yow
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

4.  Standardization and evaluation of the CAMP reaction for the prompt, presumptive identification of Streptococcus agalactiae (Lancefield group B) in clinical material.

Authors:  C L Darling
Journal:  J Clin Microbiol       Date:  1975-02       Impact factor: 5.948

5.  Subdural empyema in an infant due to group B beta-hemolytic Streptococcus.

Authors:  L Ferguson; S P Gotoff
Journal:  Am J Dis Child       Date:  1977-01

Review 6.  Group B streptococci in human disease.

Authors:  M J Patterson; A El Batool Hafeez
Journal:  Bacteriol Rev       Date:  1976-09

7.  Serious infections in adults due to group B streptococci. Clinical and serotypic characterization.

Authors:  A S Bayer; A W Chow; B F Anthony; L B Guze
Journal:  Am J Med       Date:  1976-10       Impact factor: 4.965

8.  Reaction components influencing CAMP factor induced lysis.

Authors:  B Sterzik; F J Fehrenbach
Journal:  J Gen Microbiol       Date:  1985-04

9.  The nature of staphylococcal beta hemolysin. I. Mode of action.

Authors:  G M Wiseman; J D Caird
Journal:  Can J Microbiol       Date:  1967-04       Impact factor: 2.419

10.  Rapid tube CAMP test for identification of Streptococcus agalactiae (Lancefield group B).

Authors:  E A Phillips; J W Tapsall; D D Smith
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

View more
  29 in total

1.  Identification of non-immunoglobulin A-Fc-binding forms and low-molecular-weight secreted forms of the group B streptococcal beta antigen.

Authors:  L J Brady; M D Boyle
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

Review 2.  Perinatal Group B Streptococcal Infections: Virulence Factors, Immunity, and Prevention Strategies.

Authors:  Jay Vornhagen; Kristina M Adams Waldorf; Lakshmi Rajagopal
Journal:  Trends Microbiol       Date:  2017-06-17       Impact factor: 17.079

3.  Regulation of cytotoxin expression by converging eukaryotic-type and two-component signalling mechanisms in Streptococcus agalactiae.

Authors:  Lakshmi Rajagopal; Anthony Vo; Aurelio Silvestroni; Craig E Rubens
Journal:  Mol Microbiol       Date:  2006-09-27       Impact factor: 3.501

4.  Streptococcus agalactiae CAMP factor/protein B does not bind to human IgG.

Authors:  Waseem El-Huneidi; Ryan Mui; Tian Hua Zhang; Michael Palmer
Journal:  Med Microbiol Immunol       Date:  2006-11-04       Impact factor: 3.402

Review 5.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

6.  Identification, cloning, and expression of the CAMP factor gene (cfa) of group A streptococci.

Authors:  K Gase; J J Ferretti; C Primeaux; W M McShan
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Nonimmune binding of human immunoglobulin A to type II group B streptococci.

Authors:  B F Anthony; N F Concepcion; S M Puentes; N R Payne
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Method for quantitative detection and presumptive identification of group B streptococci on primary plating.

Authors:  Søren Mose Hansen; Uffe B Skov Sørensen
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

9.  Threonine phosphorylation prevents promoter DNA binding of the Group B Streptococcus response regulator CovR.

Authors:  Wan-Jung Lin; Don Walthers; James E Connelly; Kellie Burnside; Kelsea A Jewell; Linda J Kenney; Lakshmi Rajagopal
Journal:  Mol Microbiol       Date:  2009-01-23       Impact factor: 3.501

10.  CAMP factor is not essential for systemic virulence of Group B Streptococcus.

Authors:  Mary E Hensler; Darin Quach; Chia-Jun Hsieh; Kelly S Doran; Victor Nizet
Journal:  Microb Pathog       Date:  2007-08-14       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.